AVALIAÇÃO DO ELETROCARDIOGRAMA DE PACIENTES COM LEISHMANIOSE TEGUMENTAR AMERICANA TRATADOS COM ANTIMONIAL PENTAVALENTE (GLUCANTIME®)

Abstract

The pentavalent antimonial compounds (Meglumine Antimoniate – Glucantime®) are thecornerstone for the treatment of American Cutaneous Leishmaniasis (ACL). Cardiotoxicity is theirprincipal adverse effect, which becomes evident as abnormalities in the resting Electrocardiogram(ECG), the prolongation of the corrected QT interval (QTc) being the most important and potentiallyhazardous of them. The purpose of this study was to evaluate the disturbances on ECG andSILVA DE FREITAS, P. F. et al. Avaliação Do Eletrocardiograma De Pacientes Com Leishmaniose Tegumentar Americana Tratados Com Antimonial Pentavalente (Glucantime®). Revista de Patologia Tropical, v. 43, n. 4, p. 405–411, 2014. theirfrequency in patients diagnosed with ACL and treated with Glucantime® at our Institution. Fifteenpatients between 18 and 59 years had their ECGs assessed by a senior cardiologist. The tests wereperformed prior to treatment, as well as on its 7th, 14th and 21st day. Five patients (33%) developed anabnormality not previously observed, and frequency correlated with the duration of the treatment.The most common was sinus bradycardia (5 of 15 patients), followed by prolongation of the QTcinterval (2 of 15 patients; both also had sinus bradycardia). No major cardiovascular symptomsor complications were reported. Only one patient had to interrupt the treatment. This proportionof ECG disturbances is consistent with previous studies on the subject. We conclude that thecardiotoxicity of the pentavalent antimonial drugs occurred insidiously in a percentage of patientscompatible with the literature, and was not associated with major clinical complications.